{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:46Z","timestamp":1787010226649,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"\n Background:<\/jats:title>\n Recent guidelines suggest that antiplatelet therapy (APT) is the standard of care in the absence of long-term oral anticoagulation (OAC) indications in patients post-transcatheter aortic valve replacement (TAVR). The superiority of one method over the other remains controversial.<\/jats:p>\n <\/jats:sec>\n \n Materials and methods:<\/jats:title>\n \n Several databases, including MEDLINE, Google Scholar, and EMBASE, were electronically searched. The primary endpoint was the all-cause mortality (ACM) rate. Secondary endpoints included cardiovascular death, myocardial infarction (MI), stroke\/TIA, haemorrhagic stroke, bleeding events, systemic embolism, and valve thrombosis in post-TAVR patients receiving APT and oral anticoagulants (OACs). Forest plots were generated using Review Manager version 5.4, with a\n p<\/jats:italic>\n value less than 0.05 indicating statistical significance. Subgroup analysis was performed to explore potential sources of heterogeneity.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Twelve studies were selected. No significant differences were observed in APT and OAC group for ACM [risk ratio (RR): 0.67; 95% CI:0.45\u20131.01;\n P<\/jats:italic>\n =0.05], cardiovascular death [RR:0.91; 95% CI:0.73\u20131.14;\n P<\/jats:italic>\n =0.42], MI [RR:1.69; 95% CI:0.43\u20136.72;\n P<\/jats:italic>\n =0.46], Stroke\/TIA [RR:0.79; 95% CI:0.58\u20131.06;\n P<\/jats:italic>\n =0.12], ischaemic stroke [RR:0.83; 95% CI:0.50\u20131.37;\n P<\/jats:italic>\n =0.47], haemorrhagic stroke [RR:1.08; 95% CI: 0.23\u20135.15;\n P<\/jats:italic>\n =0.92], major bleeding [RR:0.79; 95% CI:0.51\u20131.21;\n P<\/jats:italic>\n =0.28], minor bleeding [RR:1.09; 95% CI: 0.80\u20131.47;\n P<\/jats:italic>\n =0.58], life-threatening bleeding [RR:0.85; 95% CI:0.55\u20131.30;\n P<\/jats:italic>\n =0.45], any bleeding [RR:0.98; 95% CI:0.83\u20131.15;\n P<\/jats:italic>\n =0.78], and systemic embolism [RR:0.87; 95% CI:0.44\u20131.70;\n P<\/jats:italic>\n =0.68]. The risk of valve thrombosis was higher in patients receiving APT than in those receiving OAC [RR:2.61; 95% CI:1.56\u20134.36;\n P<\/jats:italic>\n =0.0002].\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Although the risk of valve thrombosis increased in patients receiving APT, the risk of other endpoints was comparable between the two groups.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/ms9.0000000000001908","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T06:02:58Z","timestamp":1710396178000},"page":"2911-2925","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and outcomes of antiplatelet therapy versus oral anticoagulants in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"86","author":[{"given":"Aman","family":"Goyal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Qayyum","family":"Abbasi","sequence":"additional","affiliation":[{"name":"Federal Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Daoud","family":"Tariq","sequence":"additional","affiliation":[{"name":"Foundation University Medical College, Islamabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Gautham","family":"Kanagala","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Metropolitan Hospital Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mah I. Kan","family":"Changez","sequence":"additional","affiliation":[{"name":"Department of Surgery, Quetta Institute of Medical Sciences, Quetta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darsh","family":"Safi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Basit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rawalpindi Medical University, Rawalpindi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia Aziz","family":"Sulaiman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Dheyaa Marsool","family":"Marsool","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Daoud","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Bogomolets National Medical University, Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir H.","family":"Sohail","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of New Mexico Health Sciences, Albuqurque, NM"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5]]},"reference":[{"key":"R1-20250806","first-page":"e011527","article-title":"Treating symptomatic aortic stenosis with transcatheter aortic valve replacement: is there time to wait?","volume":"8","author":"Faridi","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"1103760","DOI":"10.3389\/fcvm.2023.1103760","article-title":"Trends in surgical aortic valve replacement in pre- and post-transcatheter aortic valve replacement eras at a structural heart center","volume":"10","author":"Norton","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R3-20250806","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.3390\/jcm10215046","article-title":"Vascular complications in TAVR: incidence, clinical impact, and management","volume":"10","author":"Mach","year":"2021","journal-title":"J Clin Med"},{"key":"R4-20250806","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcin.2018.12.019","article-title":"The \u201cBig Five\u201d complications after transcatheter aortic valve replacement","volume":"12","author":"Grube","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"R5-20250806","first-page":"e019490","article-title":"Duration of antiplatelet therapy following transcatheter aortic valve replacement: systematic review and network meta-analysis","volume":"10","author":"Kuno","year":"2021","journal-title":"JAMA Cardiol"},{"key":"R6-20250806","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/clc.23909","article-title":"Comparison of efficacy and safety between VKAs and DOACs in patients with atrial fibrillation after transcatheter aortic valve replacement: a systematic review and meta-analysis","volume":"45","author":"Yan","year":"2022","journal-title":"Clin Cardiol"},{"key":"R7-20250806","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jcin.2021.05.025","article-title":"TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist?","volume":"14","author":"Didier","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R9-20250806","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"R10-20250806","first-page":"1","article-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","volume":"2","author":"Peterson","year":"2011","journal-title":"Ottawa: Ottawa Hospital Research Institute"},{"key":"R11-20250806","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1093\/eurheartj\/ehs255","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document","volume":"33","author":"Kappetein","year":"2012","journal-title":"Eur Heart J"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"R13-20250806","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"R15-20250806","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: The ADAPT-TAVR randomized clinical trial","volume":"146","author":"Park","year":"2022","journal-title":"Circulation"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"e009983","DOI":"10.1161\/CIRCINTERVENTIONS.120.009983","article-title":"Randomized trial of aspirin versus warfarin after transcatheter aortic valve replacement in low-risk patients","volume":"14","author":"Rogers","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1911426","article-title":"Reduced leaflet motion after transcatheter aortic-valve replacement","volume":"382","author":"De Backer","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-20250806","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jcin.2019.06.001","article-title":"Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation","volume":"12","author":"Kosmidou","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"5 Pt B","key":"R19-20250806","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.carrev.2017.12.001","article-title":"Routine use of anticoagulation after transcatheter aortic valve replacement: initial safety outcomes from a single-center experience","volume":"19","author":"Gurevich","year":"2018","journal-title":"Cardiovasc Revasc Med"},{"key":"R20-20250806","doi-asserted-by":"crossref","first-page":"649","DOI":"10.5603\/CJ.a2017.0050","article-title":"Comparison of dual antiplatelet therapy versus oral anticoagulation following transcatheter aortic valve replacement: a retrospective single-center registry analysis","volume":"24","author":"Holy","year":"2017","journal-title":"Cardiol J"},{"key":"R21-20250806","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40256-020-00443-9","article-title":"Comparison of warfarin to dual antiplatelet therapy following transcatheter aortic valve replacement","volume":"21","author":"Nei","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"R22-20250806","doi-asserted-by":"crossref","first-page":"780762","DOI":"10.3389\/fcvm.2021.780762","article-title":"Real-world anticoagulatory treatment after transcatheter aortic valve replacement: a retrospective, observational study on 4,800 patients","volume":"8","author":"Hohmann","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R23-20250806","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.amjcard.2023.06.018","article-title":"Effect of edoxaban versus antiplatelet therapy on leaflet thrombosis and cerebral thromboembolism after TAVI according to major clinical and anatomic factors in prespecified subgroup analysis from the ADAPT-TAVR trial","volume":"203","author":"Lee","year":"2021","journal-title":"Am J Cardiol"},{"key":"R24-20250806","first-page":"544","article-title":"Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation\u2014comparison of regimes","volume":"25","author":"Poliacikova","year":"2013","journal-title":"J Invasive Cardiol"},{"key":"R25-20250806","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1161\/01.CIR.0000047200.36165.B8","article-title":"Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description","volume":"106","author":"Cribier","year":"2002","journal-title":"Circulation"},{"key":"R26-20250806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5603\/KP.2018.0013","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"76","author":"Baumgartner","year":"2018","journal-title":"Kardiol Pol"},{"key":"R27-20250806","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2019.12.037","article-title":"Long-term outcomes of anticoagulation for bioprosthetic valve thrombosis","volume":"75","author":"Petrescu","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R28-20250806","first-page":"e72","article-title":"2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"R29-20250806","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Beyersdorf","year":"2022","journal-title":"Eur Heart J"},{"key":"R30-20250806","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Annals of Medicine & Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:23:37Z","timestamp":1754486617000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000001908","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"2023-12-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}